

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/603,262
				Filing Date	June 25, 2003
				Confirmation Number	2868
				First Named Inventor	Michael E. McCadden
				Group Art Unit	1615
				Examiner Name	not yet assigned
Sheet	1	of	4	Attorney Docket No.	MMCD 3080.2



U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
AWP	1	4,569,935	A	Rosenberg et al.	02/11/1986		
	2	5,110,809	A	Wang et al.	05/05/1992		
	3	5,219,877	A	Shah et al.	06/15/1993		
	4	5,478,814	A	Packman	12/26/1995		
	5	5,883,085	A	Blank et al.	03/16/1999		
	6	5,972,920	A	Seidel	10/26/1999		
AWP	7	6,391,282	B1	Dugger, III	05/21/2002		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
AWP	8	EP	173,478	A1	Horrobin et al.	03/05/1986	
AWP	9	CN	1,095,615	A	Lu et al.	11/30/1994	


Examiner Signature	Alton Pryor	Date Considered	5/28/04
-----------------------	-------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/603,262	
			Filing Date	June 25, 2003	
			Confirmation Number	2868	
			First Named Inventor	Michael E. McCadden	
			Group Art Unit	1615	
			Examiner Name	not yet assigned	
Sheet	2	of	4	Attorney Docket No.	MMCD 3080.2



FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
DWP	10	CN	1,111,984	A	Wu	11/22/1995	
DWP	11	WO	92/14472	A1	Hill et al.	09/03/1992	
DWP	12	WO	97/27862	A1	Story et al.	08/07/1997	
OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.					T ⁶
DWP	13	M. H. WORTZEL "A Double-Blind Study Comparing the Superiority of a Combination Antifungal (Clotrimazole)/Steroidal (Betamethasone Dipropionate) Product, CUTIS, Vol. 30, (8/1982) pp. 258-261.					
	14	G. V. JAFFE et al. "An Open Trial of Clotrimazole Plus Hydrocortisone Cream in the Treatment of Napkin Dermatitis in General Practice" Pharmatherapeutica, Vol. 4, No. 5 (1985) pp. 314-318.					
	15	R. E. STOUGHTON "Are Generic Formulations Equivalent to Trade Name Topical Glucocorticoids?" Archives of Dermatology, Vol. 123 (10/1987) pp. 1312-1314.					
	16	R. E. STOUGHTON "Bioassay System for Formulations of Topically Applied Glucocorticosteroids" Archives of Dermatology, Vol. 106 (12/1972) pp. 825-827.					
DWP	17	D. B. JACKSON et al. "Bioequivalence (bioavailability) of General Topical Corticosteroids" Journal of the American Academy of Dermatology, Vol. 20, No. 5, Pt. 1 (5/1989) pp. 791-796.					

Examiner Signature	Alton Pryor	Date Considered	5/28/04
-----------------------	-------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/603,262		
		Filing Date	June 25, 2003		
		Confirmation Number	2868		
		First Named Inventor	Michael E. McCadden		
		Group Art Unit	1615		
		Examiner Name	not yet assigned		
Sheet	3	of	4	Attorney Docket No.	MMCD 3080.2

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>AWP</i>	18	C. A. GUZZO et al. "Chapter 64, Dermatological Pharmacology" Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill (1996) pp. 1593-1598.	
	19	G. S. SHANKLAND et al. "Comparative in-vitro Activity of Clotrimazole and a Clotrimazole/hydrocortisone Combination in the Treatment of Experimental Dermatophytosis in Guinea Pigs" Journal of Antimicrobial Chemotherapy, Vol. 25 (1990) pp. 825-830.	
	20	R. C. CORNELL et al. "Correlation of the Vasoconstriction Assay and Clinical Activity in Psoriasis" Arch Dermatol, Vol. 121 (1/1985) pp. 63-67.	
	21	T. B. FITZPATRICK et al. "Dermatology In General Medicine, Vol. II, 4th Ed., McGraw-Hill, Inc., (1993) pp. 2444-2447 and 2847.	
	22	E.G.V. EVANS et al. "Does Naftifine Have Anti-Inflammatory Properties? A Double-blind Comparative Study With 1% Clotrimazole/1% Hydrocortisone in Clinically Diagnosed Fungal Infection of the Skin" British Journal of Dermatology, Vol. 129 (1993) pp. 437-442.	
	23	S. K. HEBEL et al. "Drug Facts and Comparisons" Facts and Comparisons, St. Louis, A Wolters Kluwer Company (1/2000) pages ii, 1658, 1659, 1684.	
	24	"Facts and Comparisons, on Aveeno® anti-itch", by Rydelle, revised May 1992, pp. 564a.	
	25	S. LEVY "Latest Switch - Lamisil - Offers to Get it Done Faster" Drug Topics, 4/19/99, pp. 72.	
	26	K. A. ARNDT et al. "Manual of Dermatologic Therapeutics" 5th Ed., Little, Brown & Co., pp. 49, 290, 309.	
	27	A. W. MCKENZIE et al. "Method for Comparing Percutaneous Absorption of Steroids" Archive of Dermatology, Vol. 86, (1962) pp. 608-610.	
<i>AWP</i>	28	"Physician's Desk Reference, on Caldryl®", by Pfizer, obtained from PDR on-line.	

Examiner Signature	<i>Alton Pryor</i>	Date Considered	<i>5/28/04</i>
--------------------	--------------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/603,262		
		Filing Date	June 25, 2003		
		Confirmation Number	2868		
		First Named Inventor	Michael E. McCadden		
		Group Art Unit	1615		
		Examiner Name	not yet assigned		
Sheet	4	of	4	Attorney Docket No.	MMCD 3080.2

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
ANP	29	V. A. PLACE et al. "Precise Evaluation of Topically Applied Corticosteroid Potency" Archives of Dermatology, Vol. 101 (5/1970) pp. 531-537.	
	30	H. I. KATZ et al. "SCH 370 (Clotrimazole-Betamethasone Dipropionate) Cream in Patients with Tinea Cruris or Tinea Corporis" Vol. 34 (8/1984) pp. 183-188.	
	31	P. WALSH et al. "Schering, Lotrisone" Physicians' Desk Reference PDR 55ed 2001, pp. 2912-2914.	
	32	A. R. W. BOWRING et al. "The Treatment of Napkin Dermatitis: a Double-Blind Comparison of Two Steroid-Antibiotic Combinations" Pharmatherapeutica, Vol. 3, No. 9 (1984) pp. 613-617.	
	33	"USP 24, NF 19" U.S. Pharmacopeia & National Formulary, The United States Pharmacopeial Convention, Inc. 12601 Twinbrook Parkway, Rockville, MD (1999) pp. 273-274, 1768-1769.	
ANP	34	R. E. STOUGHTON "Vasoconstrictor Activity and Percutaneous Absorption of Glucocorticosteroids" Archives of Dermatology, Vol. 99 (6/1969) pp. 753-756.	

Examiner Signature	Alton Pryor	Date Considered	5/28/04
--------------------	-------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.